Pulling SEC filings + quote and writing the call…

Vuzix Corp
Next earnings Aug 12, 2026 · consensus $-0.11 EPS, $1.53M rev
Last earnings -2.6% on 2026-05-15
Negative-gross-margin smart-glasses maker with collapsing revenue, ~1yr cash runway and going-concern flags trading at 37x sales — uninvestable.
Revenue $6.28M · FY2025
Vuzix fails the quality test on nearly every axis. FY2025 revenue was just $6.28M — nominally +9.1% YoY, but that 'growth' is off a gutted base: sales have more than halved from $12.1M in FY2023 and $13.2M in FY2021, so the top line is in structural decline, not recovery. Worse, the company sells its hardware below cost: gross profit was -$1.06M (gross margin -16.9%), meaning more revenue actually destroys more value before a dollar of opex. Layer on $12.6M of R&D (+31%) and the result is a -$32.5M operating loss, -517% operating margin, and a -130.8% ROE. Five straight years of $30M-$73M net losses have built a -$400M accumulated deficit — this is not a young company on the cusp of scale; it is a two-decade cash-burn story.
The balance sheet buys limited time, not safety. Cash of $21.2M against operating cash burn of -$18.8M plus $2.0M capex implies roughly one year of runway. The 10-K explicitly lists 'going concern' among its critical accounting estimates and warns it 'would be required to raise additional capital' that it 'may not be able to raise on commercially reasonable terms or at all.' Shares already grew +9.1% in the year, so the near-certain equity raise means further dilution of an 83.2M share base — a direct headwind to per-share value. The only bright spots — no long-term debt and a benign 0.22x liabilities/equity — are cold comfort when equity itself fell 33.8% and is being consumed by losses.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 3, 2026, 7:05 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $13.2M | $11.8M | $12.1M | $5.75M | $6.28M |
| Gross profit | $1.57M | $1.48M | -$2.63M | -$5.60M | -$1.06M |
| Operating income | -$40.0M | -$42.2M | -$52.3M | -$74.0M | -$32.5M |
| Net income | -$40.4M | -$40.8M | -$50.1M | -$73.5M | -$32.3M |
| Diluted EPS | -$0.66 | -$0.64 | -$0.79 | -$1.08 | -$0.42 |
| Net margin | -306.7% | -344.4% | -413.5% | -1277.9% | -513.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting voting results (Item 5.07) — directors elected, routine proposals passed
Q1 2026 results release: revenue tiny, losses continue amid AR/AI glasses push
Q1 2026 10-Q: cash burn continues, $21M cash cushion funds near-term ops
Executive/board change (Item 5.02) — officer or director appointment/departure
Proxy for 2026 annual meeting — board, comp and routine governance votes
Executive/board change (Item 5.02) — officer or director appointment/departure
FY2025 results: net loss narrowed 56% to $32.3M, revenue +9% to $6.28M
FY2025 10-K flags going-concern; $400M accumulated deficit, more capital likely needed
Amended shelf registration — sets up further equity sales, dilution overhang
Sources: SEC EDGAR (CIK 0001463972, latest 10-Q filed 2026-05-14) · EODHD · Proprietary analysis · as of 7/3/2026, 11:05:42 AM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 2 sales
| 2026-05-26 | Whitten-Doolin Paula Beck Director | Sell | 32.0K @ $4.68 | $150K |
| 2026-05-21 | Harned Timothy Heydenreich Director | Sell | 10.0K @ $4.73 | $47.3K |
| 2026-03-04 | Parkinson Christopher Iain See remarks | Sell | 11.7K @ $2.69 | $31.4K |
| 2025-12-22 | Parkinson Christopher Iain See Remarks | Sell | 9.46K @ $2.92 | $27.6K |
| 2025-09-29 | Parkinson Christopher Iain See Remarks | Award | 150K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1195 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.